Clinical trial · Interventional
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: The combination of anti-angiogenic targeted therapy with neoadjuvant chemotherapy has been shown to further improve the pathologic response rate for HER2-negative breast cancer patients. Apatinib is a highly potent human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor that has been independently developed in China, and it can exert anti-angiogenic effects by inhibiting VEGFR2. It is unknown whether giving combination neoadjuvant chemotherapy together with apatinib is more effective in treating patients with nonmetastatic HER2-negative breast cancer. PURPOSE: To explore the efficacy and safety of apatinib added to weekly paclitaxel and cisplatin neoadjuvant therapy for HER-2 negative breast cancer patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apatinib | Drug | — | UNRESOLVED |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Apatinib+Paclitaxel+Cisplatin
- interventionNames
- Drug: Apatinib
- Drug: Paclitaxel
- Drug: Cisplatin
- Procedure: Surgery
- type
- ACTIVE_COMPARATOR
- label
- Arm II
- description
- Paclitaxel+Cisplatin
- interventionNames
- Drug: Paclitaxel
- Drug: Cisplatin
- Procedure: Surgery
Primary outcomes (2)
- measure
- Residual cancer burden (RCB 0-I rates）
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18\~70 year-old，Female 2. Patients with histologically confirmed primary invasive breast adenocarcinoma,cT2-4N0-3M0 3. ECOG 0-1 4. HER2-negative tumor in biopsy, defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ confirmed as FISH negative. 5. Adequate organ function Exclusion Criteria: 1. Unwilling to use adequate contraceptive protection during the process of the study and for at least 8 weeks after the last dose of study drug. 2. Pregnant or breastfeeding patients 3. Metastatic or recurrent patients 4. Any evidence of sense or motor nerve disorders 5. Any concurrent malignancy other than breast cancer 6. Uncontrolled hypertension with hypotensive drugs therapy (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg). Patients with grade I or above myocardial ischemia or myocardial infarction or arrhythmia (including QT interval ≥ 440 ms) or cardiac insufficiency 7. Inability to swallow, gastrointestinal resection, chronic diarrhea and obstruction of the intestine, various factors which affect drug use and absorption 8. Coagulation disorders 9. Artery or venous thrombosis occurred within 6 months before the study begins 10. Have received prior treatment with a VEGFR TKI
References
Publications (0)
Data not yet available